Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2343]

KRAS/NRAS and BRAF mutations in study of panitumumab plus FOLFIRI for second...

Prof Marc Peeters - University of Antwerp, Antwerp, Belgium

KRAS/NRAS and BRAF mutations in study of panitumumab plus FOLFIRI for second-line treatment of mCC ( Prof Marc Peeters - University of Antwerp, Antwerp, Belgium )

Comment: HPV-targeted adoptive T cell therapy may provide a new strategy for...

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: HPV-targeted adoptive T cell therapy may provide a new strategy for advanced cervical cancer ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid...

Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer ( Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France )

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute...

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

$Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )$

Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck...

Prof Anthony Cmelak - Vanderbilt-Ingram Cancer Center, Nashville, USA

Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers ( Prof Anthony Cmelak - Vanderbilt-Ingram Cancer Center, Nashville, USA )

ASCO 2014 roundup

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ASCO 2014 roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early...

Dr Edith Perez - Mayo Clinic, Rochester, USA

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer ( Dr Edith Perez - Mayo Clinic, Rochester, USA )

ASCO 2014: Advances in prostate cancer discussion

Prof Noel Clarke; Dr Cora Sternberg; Dr Kurt Miller, Prof Wysocki

ASCO 2014: Advances in prostate cancer discussion ( Prof Noel Clarke; Dr Cora Sternberg; Dr Kurt Miller, Prof Wysocki )

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early...

Dr Edith Perez - Mayo Clinic, Rochester, USA

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early-stage HER2-positive breast cancer ( Dr Edith Perez - Mayo Clinic, Rochester, USA )

Adjuvant exemestane more effective than tamoxifen when combined with ovarian...

Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona...

Adjuvant exemestane more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer ( Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

Targeted drug combo, cediranib plus olaparib, significantly increases...

Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA

Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer ( Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA )

Lenvatinib yields high response rates and delays progression in radioiodine...

Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France

Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer ( Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France )

More from ecancer